The effect of 10 peptides structurally related to the growth hormone (GH) releasing peptide hexarelin, injected into the paraventricular nucleus of the hypothalamus (PVN), on penile erection was studied in male rats. Six out of the 10 peptides tested induced penile erection in a dosedependent manner. Among them, the most potent were EP 80661, EP 60761 and EP 91072, which were active at doses of 20 ± 200 ng. The potency of these peptides in inducing penile erection is comparable to that of apomorphine, oxytocin and N-methyl-D-aspartic acid similarly injected into the PVN. Other peptides found active were EP 50885, EP 90101 and EP 91071, which induced penile erection at doses of 200 ± 2000 ng. In contrast, EP 51322, EP 70555, EP 51216 and EP 91073 were inactive, as were hexarelin, EP 40904 and EP 40737 in a previous study. The majority of EP peptides found active when injected into the PVN induced penile erection, although to a lesser extent, also when given systemically (endovenously). The proerectile effect of EP peptides was prevented by the oxytocin receptor antagonist [d(CH 2 ) 5 Tyr(Me) 2 -Orn 8 ]-vasotocin given into the lateral ventricles but not into the PVN, by the nitric oxide (NO) synthase inhibitor N G -nitro-larginine methyl ester given either into the lateral ventricles or into the PVN, by the N-type Ca 2 channel blocker o o-conotoxin GVIA and by morphine, but not by the dopamine receptor antagonist cis-¯upenthixol or by the N-methyl-D-aspartic acid receptor antagonist dizolcipine, given into the PVN. As the structure ± activity relationship of EP peptides for proerectile activity is different from those of other biological actions of these compounds, ie for GH release and eating behaviour, the present results suggest that EP peptides induce penile erection by acting on speci®c hypothalamic receptor sites that activate paraventricular oxytocinergic neurons projecting to extrahypothalamic brain areas that mediate this sexual function by a mechanism similar to that of dopamine receptor agonists, oxytocin and N-methyl-D-aspartic acid.
Introduction
Penile erection is a male sexual response that plays a key role in the reproduction of mammals, including humans. However, this sexual response can be observed also in contexts not strictly related to reproduction (ie copulation and sexual intercourse), for instance during the manipulation of genitalia, erotic fantasies and REM sleep in humans, after the retraction of the penile sheath in restrained rats, after the injection of drugs andaor neuropeptides or when freely moving male rats are put in the presence of an inaccessible receptive female. Depending on the context in which penile erection occurs, different central and peripheral neural anda or humoral mechanisms are thought to participate in its regulation. 1 ± 5 Among neurotransmitters and neuropeptides involved at the central level in the control of penile erection, the best known are dopamine, serotonin, excitatory and inhibitory amino acids, nitric oxide (NO), adrenocorticotrophin and related peptides, oxytocin and opioid peptides. They facilitate or inhibit penile erection by acting in several brain areas, namely the medial preoptic area, the paraventricular nucleus of the hypothalamus (PVN), the hippocampus, the amygdala, the bed nucleus of the stria terminalis, the medulla oblongata and the spinal cord. 1 ± 6 In particular, there is huge experimental evidence to suggest that central oxytocinergic neurons originating in the PVN and projecting to extrahypothalamic brain areas (the hippocampus, the medulla oblongata and the spinal cord) play an important role in the control of penile erection. Accordingly, dopamine receptor agonists, the excitatory amino acid receptor agonist N-methyl-D-aspartic acid (NMDA) and oxytocin itself activate these oxytocinergic neurons and, conversely, opiate compounds and the GABA receptor agonist muscimol inhibit the activity of these neurons and prevent penile erection induced by the aforementioned compounds. 2, 7 The stimulation of oxytocinergic neurons mediating penile erection seems secondary to the activation of NO synthase in the PVN. Indeed (1) NO synthase inhibitors prevent dopamine receptor agonist Ð NMDA Ð and oxytocin-induced penile erection, 2 (2) classic NO donors induce penile erection when injected into the PVN by increasing oxytocinergic transmission, 2 (3) dopamine receptor agonists, NMDA and oxytocin increase NO production in the PVN when given at doses that induce penile erection, as shown by in vivo microdialysis, both responses being prevented by the NO synthase inhibitor N G -nitro-l-arginine methyl ester (L-NAME) injected into the PVN. 8 ± 10 Recently we found that EP 60761 and EP 50885, two peptide analogues of hexarelin, a growth hormone (GH) releasing peptide, 11, 12 but not EP 40737, EP 40904 or hexarelin itself, were both able to induce penile erection episodes indistinguishable from those induced by the dopamine receptor agonist apomorphine, by oxytocin or by NMDA, when injected into the PVN of male rats, in a way apparently irrespective of their effect on GH release or eating behaviour. 13 The facilitatory effect of both EP peptides on penile erection was prevented by the oxytocin receptor antagonist [d(CH 2 ) 5 Tyr(Me) 2 -Orn 8 ]-vasotocin 14 given into the lateral ventricles (i.c.v.) but not into the PVN, by the NO synthase inhibitor L-NAME 15 given i.c.v. or into the PVN, by morphine, but not by the NMDA receptor antagonist dizolcipine (( )MK-801) 16 or by the dopamine receptor antagonist cis-¯upenthixol, all given into the PVN. 13 This led us to suggest that these peptides when injected into the PVN induce penile erection by activating central oxytocinergic transmission, as previously suggested for dopamine receptor agonists (ie apomorphine), NMDA and oxytocin itself. In particular, EP 60761 induced penile erection at doses as low as 20 ng (70 pmoles), 13 that is with a proerectile potency comparable to that reported for apomorphine, oxytocin and NMDA when injected into the PVN. 17 ± 19 The present study was aimed at pursuing the identi®cation of other EP 60761-andaor EP50885-related peptides endowed with proerectile activity when injected into the PVN and to compare their structure ± activity relationship with that of those peptides well characterized for their effects on GH release and eating behaviour. 20 A comparison of the proerectile effects of these EP peptides with those of apomorphine, oxytocin and NMDA, and the effect they induced on penile erection when given systemically (endovenously) are also reported.
Materials and methods

Animals
Male Sprague ± Dawley rats (200 ± 220 g)(Charles River, Como, Italy) were used in all the experiments. The animals were caged in groups of 4 ± 6 at 24 C, humidity 60%, lights on from 07:00 to 19:00 h with water and standard laboratory food ad libitum. The experiments were performed between 09:00 and 13:00 h.
Drugs and peptides
The following peptides: EP 50885, EP 60761, EP 80661, EP 70555, EP 51216, EP 90101, EP 51322, EP 91071, EP 91072 and EP 91073 (see Table 1 
Abbreviations: GAB gamma-amino-butyryl; AIB amino-isobutyryl; bNal b-(2-naphthyl)-alanine. 21 Each rat was used only once. The same guide cannula was used for i.c.v. and PVN injections. For i.c.v. injections, all substances were injected in a volume of 10 ml of saline in 1 min, via an internal cannula (28 gauge) which extended 1 mm below the tip of the guide cannula and was connected by polyethylene tubing to a 10 ml Hamilton syringe driven by a micrometric screw. Control rats received 10 ml of physiologic saline. After injection the tip of the cannula was left in the injection site for 30 s to allow the spread of the injected solution. For PVN injections all substances were injected in a volume of 0.3 ml of saline, within 2 min through an internal cannula that extended 5.3 mm below the tip of the guide cannula and was connected by a polyethylene tubing to a 10 ml Hamilton syringe driven by a Stoelting microinfusion pump. Controls received 0.3 ml of saline in the PVN. After microinjection, the tip of the cannula was left in the injection site for 30 s to allow the spread of the injected solution.
Systemic administration
For systemic administration, a polyethylene-made cannula exiting from the back of the animals was implanted into the jugular vein under chloral hydrate anaesthesia. After implantation the cannula was ®lled with heparin and closed by a cotton thread until an injection was made. Peptides were dissolved in physiologic saline and injected in a volume of 80 ml after a prior injection of 80 ml of saline to cannula of the heparin, and followed by another 80 ml of saline and by 80 ml of heparin to avoid the cannula occlusion. All other experimental conditions were identical to those described above for PVN and i.c.v. injections.
Behavioural studies
When dose ± response curves were performed, the peptides, apomorphine, oxytocin, NMDA, all dissolved in saline, or saline alone (0.3 ml) were microinjected into the PVN of rats implanted with chronic guide cannulas within a 2 -min period.
Orn 8 ]-vasotocin, L-NAME, ( )MK-801 and cisupenthixol were used, these compounds were dissolved in saline and injected into the PVN of rats implanted with chronic guide cannulas within a 2 -min period, 10 min before one of the peptides under study. The same schedule was followed when [d(CH 2 ) 5 Tyr(Me) 2 -Orn 8 ]-vasotocin or L-NAME was injected i.c.v., the only exception being a quicker injection time (1 min). Shortly after all treatments the animals were placed individually into Plexiglas cages (30 6 30 6 30 cm) and were observed for 60 min, during which penile erection episodes were counted by an observer who was unaware of the treatments to eliminate subjective evaluations.
Histology
At the end of the experiments the animals were killed by decapitation, the brains were immediately removed and stored in 2% aqueous formaldehyde for 10 ± 12 days. To localize the injection site 50-mm transverse brain sections were prepared by means of a freezing microtome, stained with Neutral Red and inspected on a phase-contrast microscope. The injection site was localized by following the internal cannula tract through a series of brain sections. Only those animals found to have the internal cannula tip positioned correctly i.c.v. or in the PVN were included in the statistical evaluation of the results.
Statistics
Statistical evaluation of the results was performed by one-way analysis of variance (ANOVA) followed by Duncan's multiple range test for the comparison of differences among multiple groups. Student's ttest was used to compare differences between two groups. A P`0.025 was considered signi®cant.
Results
Effect of EP peptides injected into the PVN on penile erection: dose ± response curves EP peptides were tested for their ability to induce penile erection when injected into the PVN of male rats at doses of 20, 200, 1000 and 2000 ngarat. Of the 10 peptides tested, EP 80661, EP 91071, EP 91072 and EP 90101 were active in inducing penile erection, in addition to the previously identi®ed EP 60761 and EP 50885 (Figure 1 ). The effect of these peptides on penile erection was clearly dosedependent. EP 80661, which differs from EP 60761 for having only two D-Trp(Me) residues instead of three, and EP 91072, which differs from EP 80661 for having two D-Trp residues instead of two DTrp(Me) residues (Table 1) , were as potent as EP 60761, being already active at a dose of 20 ng. The maximal effect was obtained with these three peptides at a dose of 200 ng. EP 91071 and EP 90101 were also able to induce penile erection dosedependently, although their potency was lower than that of EP 60761, EP 80661 and EP 91072. Indeed, the dose ± response curves of EP 90101 and EP 91071 were similar to that of EP 50885, ie minimal effective dose b 200 ng; maximal effective dose 2000 ng. EP 91071 was slightly less potent than EP 50885 and EP 90101. EP 51322, EP 70555, EP 51216 and EP 91073 were all inactive on penile erection even at the highest dose tested. 
Effect of EP peptides injected systemically on penile erection
EP 80661, EP 60761, EP 91071, EP 91072, EP 50885 and EP 90101, previously found active in inducing penile erection when injected into the PVN, were also tested for their proerectile effect after systemic (i.v.) injection (10 and 50 mgarat). As shown in Figure 3 , a small but signi®cant effect was present with EP 80661, EP 91072, EP 91071, EP 50885 and EP 90101, but not with EP 60761 (50 mgarat). At this Figure 1 Effect of EP peptides injected into the PVN on spontaneous penile erection: dose ± response curves. The peptides were dissolved in physiological saline and injected into the PVN in a volume of 0.3 ml as described in the Materials and methods section. Rats injected with 0.3 ml of saline alone were used as controls. After treatment rats were placed individually into Plexiglas cages and observed for 60 min, to count penile erection episodes. Values are means AE s.e.m. of eight rats per group. *P`0.01 vs saline-treated rats (one-way ANOVA, followed by Duncan's multiple range test). and cis-¯upenthixol (10 mg) given into the PVN were ineffective. These compounds exerted similar effects on EP 60761-and EP 50885-induced penile erection. 13 
Discussion
The present study con®rms and broadens previous ®ndings showing that EP peptides related to hexarelin, eg EP 80661, EP 91072, EP 91071 and EP 90101, in addition to EP 60761 and EP 50885, induced penile erection episodes indistinguishable from those induced by apomorphine, oxytocin and NMDA, when injected into the rat PVN. As shown Figure 3 Effect of EP peptides given systemically on penile erection. EP peptides were injected endovenously in a volume of 80 ml. Rats treated with 80 ml of saline alone were used as controls. After treatment rats were placed individually into Plexiglas cages and observed for 60 min, to count penile erection episodes.
Values are means AE s.e.m. of 15 rats per group. *P`0.01 vs salinetreated rats (one-way ANOVA, followed by Duncan's multiple range test). ]-vasotocin and L-NAME were also given i.c.v. in a volume of 10 ml of saline 15 min before each one of the EP peptides. After treatment rats were placed individually into Plexiglas cages and observed for 60 min, to count penile erection episodes. Values are means AE s.e.m. of seven rats per group. *P`0.01 vs saline-pretreated rats (one-way ANOVA, followed by Duncan's multiple range test).
previously for EP 60761 and EP 50885, 13 the facilitatory effect of these peptides on penile erection was dose-dependent. Two of these peptides, EP 80661 and EP 91072, induced the sexual response at doses as low as 20 ng, as found previously with EP 60761, whereas EP 90101 and EP 91701 were active only at doses higher than 200 ng, as found with EP 50885. Accordingly, the dose that induces 50% of the maximal effect is % 70 pmoles for EP 60761, % 90 pmoles for EP 80661, % 75 pmoles for EP 91072, % 1260 pmoles for EP 50885, % 1240 pmoles for EP 90101 and % 4400 pmoles for EP 91071. However, regarding the ef®cacy, the maximal effect of EP peptides was slightly lower than that of apomorphine and of oxytocin (3.4 versus 4.5 penile erectionsarat), although similar to that of NMDA (3.7 penile erectionsarat).
The analysis of the amino acid sequence of the EP peptides tested shows the existence of a clear structure ± proerectile activity relationship. First, the presence of a basic C-terminal amino acid (Lys or Arg) seems necessary for the proerectile activity, since EP 51322, which lacks such a C-terminal amino acid is inactive. When Arg is at the Cterminal, the presence of a NO 2 group in the guanydil moiety of the amino acid, as in EP 70555, eliminates the proerectile activity. The C-terminal amino acid can be preceded by one or more aromatic amino acid residues, D-Trp As EP 80661 and EP 60761, which contain two and three D-Trp(2-Me) residues, respectively, are more potent than EP 91071, which contains only one D-Trp(2-Me) residue, the presence of two DTrp(2-Me) groups seems important for increasing the proerectile activity of EP peptides. This is not in¯uenced by the deletion of the methyl groups present in the D-Trp(2-Me) moiety, since EP 91072, which contains two D-Trp groups, is as potent as EP 80661 and EP 60761 at least when injected into the PVN. However, replacement of these two D-Trp(2-Me) residues with D-b-Nal-L-Phe, as in EP 50885, decreases the proerectile potency by about 10-fold. Also, the N-terminal amino acid seems to have a role in the proerectile activity of EP peptides. Indeed, EP 91073, which differs from EP 80661 only for having a N-terminal AIB (amino-isobutyryl) group instead of a GAB (gamma-amino-butyryl) group, is inactive, while EP 80661 is already active at a dose of 20 ng. Some of the above peptides, in particular EP 50885, EP 80661, EP 90101, EP 91072 and EP 91071, are also active when injected systemically. However, the effect of these EP peptides given systemically on penile erection is modest when compared to the effect seen after injection into the PVN. This may be due to the low amounts of EP peptides that reach the central nervous system. Interestingly, downsizing of the amino acid sequence of the EP peptides used in this study seems to increase the amount of EP peptide that reaches the central nervous system. Indeed, EP 91071, which differs from EP 80661 for having only one D-Trp(2-Me) residue instead of two between the GAB amino terminal residue and the carboxy terminal LysNH 2 is as active as EP 80661 when given systemically, although % 60 times less potent than EP 80661 when injected into the PVN, and EP 60761, which contains three D-Trp(Me) residues, is inactive when given systemically, but it is as potent as EP 80661 when injected into the PVN.
The mechanism(s) by means of which EP peptides induce penile erection when injected into the PVN is unknown at present. The existence of a structure ± activity relationship for erectile activity, which is different from that for the GH-releasing activity and that on eating behaviour of these peptides (see Table 2 ), favours our previous view that the proerectile effect of EP peptides is mediated at the PVN level by an action of these peptides on speci®c receptor sites, whose activation is conveyed to oxytocinergic neurons mediating penile erection that originate in the PVN and project to extrahypothalamic brain areas. 13 Accordingly, the facilitatory effect of the active EP peptides on penile erection was prevented by [d(CH 2 ) 5 Tyr(Me) 2 -Orn 8 ]-vasotocin, a potent and selective oxytocin receptor antagonist, 14 by L-NAME, a potent NO synthase inhibitor, 15 and by o-conotoxin-GVIA, a potent blocker of Ca 2 channels of the N-type, 22 as found previously with EP 60761 and EP 50885. 13 A similar mechanism is thought to mediate apomorphine-, oxytocin-and NMDA-induced penile erection at the PVN level. 2 19, 23 The ability of L-NAME given i.c.v. or into the PVN to prevent EP 80661-and EP 91072-induced penile erection, as found with EP 60761 and EP 50885, 13 suggests that the activation of oxytocinergic transmission by these peptides is apparently mediated by an increased NO production in the PVN, as found with oxytocin-, apomorphineand NMDA-induced penile erection. 8 ± 10 As EP peptides-induced penile erection was prevented by o-conotoxin-GVIA, which blocks N-type Ca 2 channels, 22 when injected into the PVN, the activation of NO synthase by EP peptides alluded to above, might be secondary to an increased Ca 2 in¯ux, possibly in the cell bodies of oxytocinergic neurons mediating penile erection Ð as found with the other stimulants of penile erection. 19, 24, 25 Interestingly, an increased Ca 2 in¯ux has been also shown to modulate the GH release induced by GH releasing peptides from the pituitary gland. 26, 27 Finally, that EP peptides may induce penile erection by activating oxytocinergic transmission is also supported by the ability of morphine injected into the PVN to prevent EP peptides-induced penile erection. Reportedly, morphine reduces oxytocin-, apomorphine-and NMDAinduced penile erection by apparently preventing the activation of NO synthase induced by these substances at the PVN level. 28, 29 The proposition that EP peptides induce penile erection by acting on speci®c receptors possibly coupled to Ca 2 channels and located in the cell bodies of oxytocinergic neurons is supported not only by a distinct structure ± activity relationship for this speci®c effect when compared to other biological effects of these peptides, but also by other experimental ®ndings. First, speci®c receptors and receptor messenger RNA for GH releasing peptides have been identi®ed in the pituitary gland, in the hypothalamus and in other brain regions 30 ± 34 and very recently, and endogenous ligand speci®c for GH releasing peptide receptor has been characterized. 35 Second, perhaps more relevant to our study, the activation of these receptors by GH releasing peptides induces the release of GH from the pituitary gland by increasing Ca 2 in¯ux in the somatotropes. 26, 27 Third, several lines of experimental evidence suggest the existence of different kinds of receptors for these peptides not only in the brain but also in other tissues. 20,36 ± 39 However, other possible mechanisms by means of which EP peptides act in the PVN to induce penile erection cannot be ruled out. Namely, EP peptides might alter the release of neurotransmitters andaor neuropeptides that in¯uence this function at the PVN level, eg dopamine, oxytocin, excitatory amino acids, opioid peptides and others as well. However, the likelihood of this event is scarce, since the blockade of paraventricular dopamine, oxytocin and excitatory amino acid receptors by cis-¯upenthixol, by [d(CH 2 ) 5 Tyr(Me) 2 
Conclusion
This study shows that several EP peptides related to hexarelin, a GH releasing peptide, induced penile erection when injected into the PVN of male rats in a dose-dependent manner, apparently by acting on speci®c receptors that, ultimately, activate oxytocinergic transmission. This effect was apparently divorced from their effects on GH release and eating behaviour. Some of these peptides showed a potency in inducing penile erection that is comparable to that of other agents known to induce this sexual response by acting at the PVN level (eg apomorphine, oxytocin and NMDA), and were active also when injected systemically. Since drugs that induce penile erection in rats induce this sexual response in other laboratory animals and often also in man, 2 the ®nding raises the possibility that these or related molecules with better oral bioavailability might be useful for the treatment of erectile dysfunction of central origin.
